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Background: Ovarian cancer is the most lethal gynecologic disease due to delayed diagnosis, and ascites
production is a characteristic of patients in advanced stages. The aim of this study was to perform the proteomic
analysis of ascitic fluids of Mexican patients with ovarian carcinoma, in order to detect proteins with a differential
expression pattern in the continuing search to identify biomarkers for this disease.
Methods: Samples were collected from 50 patients from the Instituto Nacional de Cancerología of México under
informed consent and with approval of the bioethics and scientific committees. After elimination of abundant
proteins (Albumin/IgGs) samples were processed for 2D electrophoresis and further protein identification by Mass
Spectrometry (MALDI-TOF). Molecules of interest were followed by western blot and lectin binding assays, and their
tissue location by histo-immunofluorescence and confocal analysis.
Results and discussion: An area with a differential expression pattern among samples was located in the 2D gels.
Identified proteins were 6 alpha 1 isoforms and 1 alpha 2 isoform of Haptoglobin, and 2 isoforms of Transthyretin.
While Transthyretin isoforms were constitutively expressed in all samples, clear differences in the expression pattern
of Haptoglobin alpha isoforms were found. Moreover, increased levels of fucosylation of Haptoglobin alpha
isoforms analyzed in 40 samples by Aleuria aurantia lectin binding by 1D overlay assay showed a positive
correlation with advanced stages of the disease. Tissue detection of Haptoglobin and its fucosylated form, by
histo-immunofluorescence in biopsies of ovarian cancer, also showed a correlation with ovarian cancer progression.
Moreover, results show that fucosylated Haptoglobin is produced by tumor cells.
Conclusions: Increased numbers of highly fucosylated Haptoglobin alpha isoforms in ascitic fluids and the
presence of fucosylated Haptoglobin in tumor tissues of ovarian cancer Mexican patients associated with advanced
stages of the disease, reinforce the potential of fucosylated Haptoglobin alpha isoforms to be characterized as
biomarkers for disease progression.
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Epithelial ovarian cancer (ovarian carcinoma) is the most
lethal gynecologic malignancy worldwide [1]. In the latest
data recorded by GLOBOCAN compiled in 2008, Mexico
reported an annual incidence of 2,910 cases and a mortality
of 1,851 Mexican women during that year (http://globo-
can.iarc.fr). According to the Mexican National Cancer In-
stitute, ovarian cancer is at the fifth position among the 10
most frequent causes of hospital mortality during 2012
(www.incan.edu.mx/). The high mortality rate is attribut-
able to the asymptomatic nature of the early stage of the
disease, the lack of established screening tests, and the de-
velopment of drug resistance [2-5].
Like most other epithelial tumors, ovarian carcinoma
spreads initially into adjacent organs, specially the fallo-
pian tubes and uterus. It then disseminates via the trans-
coelomic route, affecting many vital organs within the
abdomen including the gastrointestinal and genitourinary
systems [6,7]. Over 30% of patients present accumulation
of peritoneal fluid or ascites as a sign associated with ad-
vanced stages of the disease; and the shedding of malig-
nant cells from the surface of the ovarian tumor into the
peritoneal cavity is a common scenario in the progression
of ovarian carcinoma [6,8].
Body fluids constitute an excellent media for biomarker
discovery, and ascitic fluids usually contain malignant epi-
thelial cells and activated mesothelial cells, which can pro-
duce cytokines, growth factors, and invasion-promoting
components associated with invasion and metastasis
[9,10]; this fluid therefore, contains the secretome of ovar-
ian cancer cells and the analysis of ascites may facilitate
discovery of more sensitive and specific biomarkers than
those currently available [11].
Several authors have performed proteomic studies in
ascites and tumors from ovarian patients describing new
biomarkers; among them, E-cadherin and IL-8 as single
biomarkers [12,13] or multimarker as CA-125 in com-
bination with macrophage chemotactic protein-1, with
leptin, with HE4 or with soluble mesothelin related pro-
tein [14-16] have been described. They possess accept-
able characteristics for their possible use in population
screening, to differentiate among benign and malignant
tumors versus healthy controls, and to be used as moni-
toring biomarkers during cancer progression [17,18].
In this study, we present a proteomic analysis of 50
human ascitic fluids from ovarian carcinoma patients
and whose results show, for the first time, clear differ-
ences in the profile of Haptoglobin (Hp) alpha isoforms,
the presence of genotypes, and the differential fucosyla-
tion pattern of the same isoform among samples. More-
over, the presence of fucosylated Hp was confirmed in
pathology samples of the same cases. Results suggest an
association between the Hp alpha subunit and the fuco-
sylation level with advanced stage of the disease.Methods
Patients
The study was conducted with ascitic fluids obtained
from 50 patients diagnosed with ovarian carcinoma who
were admitted to the Instituto Nacional de Cancerología
de México. All patients were admitted for a first-time
diagnosis; the histopathology and tumor grade were
assigned by a pathologist according to the International
Federation of Gynecology and Obstetrics (FIGO) criteria
[19]. The study was approved by the Institutional Scientific
and Bioethics Committees (protocol numbers INCAN/
CC/134/09 and CB/549/09), and written consent was ob-
tained from patients prior to sample collection.
Samples
Ascitic fluids samples from patients with ovarian carcin-
oma were obtained under sterile conditions by a qualified
medical doctor. Once collected, they were transported to
the laboratory in an ice bucket. Samples were centrifuged
at 1500 × g for 10 min at 4°C. Supernatants were stored
at −70°C until assayed.
Two-dimensional (2D) gel electrophoresis of
ascitic proteins
High-abundance proteins (albumin and IgG) were re-
moved from the ascitic fluid using Vivapure anti HSA/IgG
for Human albumin and an IgG depletion kit (Sartorius
Stedim Biotech, Cat. No. VS-P08HAIGG), according to
the manufacturer’s protocol. Ascites fluids depleted from
HSA/IgG (200 μg) were cleared of salts contamination
with a ProteoExtract Protein Precipitation Kit (Calbio-
chem, Cat. No. 539180) as per manufacturer’s protocol.
Pellets were processed as described [20]. Briefly, samples
were diluted in rehydration buffer containing 8 M urea,
0.5% (w/v) CHAPS, 10 mM DTT, 0.001% bromophenol
blue, and Bio-Lyte 3–10 Ampholyte (0.2%) (Bio-Rad, Cat.
No.163-1113). The protein mixture was then applied to
ReadyStrip™ IPG 7 cm strips, pH 5–8 (linear) (Bio-Rad,
Cat. No. 163–2004). Rehydrated strips were isoelectrically
focused using a PROTEAN IEF cell System (Bio-Rad, Cat.
No. 165–4000). To perform the second dimension ana-
lysis, the strips were processed by 15% SDS-PAGE and a
Protean II XL Cell System was used. Finally the 2D gels
were stained with Silver Stain Plus (Bio-Rad, Cat. No.
161–0449).
Protein identification by MALDI-TOF
Silver-stained 2D gels were scanned in a GS-800 densi-
tometer (Bio-Rad, Hercules, CA). Digital images were
compared using the Melanie 7.0 software (GE Health-
care). Each of the 50 ascitic fluid samples was run three
times. The electrophoretic entities of interest were ex-
cised, alkylated, reduced, digested in a Proteineer line
(Bruker Daltonics, Bremen) with the aid of a DP
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essed by a MALDI-TOF Autoflex (Bruker Daltonics) to ob-
tain a peptide mass fingerprint. Peak lists of the tryptic
peptide masses were generated using FlexAnalysis1.2vSD1
Patch 2 (Bruker Daltonics) [21]. The search engine MAS-
COT server 2.0 was used to compare the fingerprints
against human taxonomy with the following parameters:
one missed cleavage allowed, carbamidomethyl cysteine as
the fixed modification and oxidation of methionine as the
variable modification. Proteins with scores greater than 50
and a p < 0.05 were accepted.
Western blot and lectin binding assays
Proteins from the ascitic fluid samples (50 μg) were sepa-
rated either by a 15% or 12.5% SDS-PAGE and transferred
to nitrocellulose membranes for subsequent detection of
Hp and fucosylated-Hp. Filters were blocked with TBS-T-
5% milk, and incubated with anti-Hp antibody (Abcam,
Cat. No. ab90924), followed in the case of the 15% SDS-
PAGE by a goat anti-mouse IgG-Alkaline Phospatase con-
jugated antibody (PIERCE, Cat. No. 31320), and in the
case of the 12.5% SDS-PAGE by a goat anti-mouse IgG
HRP-conjugated antibody (PIERCE, Cat. No. 31430). The
filter was then revealed by chemoluminescence (Super-
signal West Femto Luminol, Thermo Scientific, Cat. No.
1856189). Duplicate filters were used for fucosylation ana-
lysis. Biotinylated Aleuria aurantia lectin (AAL) (Vector
Labs, Cat. No. B-1395) purified from mushrooms [22] was
selected to specifically detect fucosylation of Hp alpha due
to its ability to bind preferentially to fucose-linked (α -1,6)
to N-acetylglucosamine structures (glycosylation’s core).
The membranes were incubated in PBS containing ap-
proximately 20 μg/ml AAL. Following this, the membrane
containing the samples from the 15% SDS-PAGE was in-
cubated with alkaline phosphatase-Streptavidin (Vector
Labs, Cat. No. SA-5100), and with the substrate for alka-
line phosphatase, BCIP/NBT (Cat. No. SK-5400). The
membrane containing the samples from the 12.5% SDS-
PAGE was incubated with HPR-streptavidin (Sigma
Aldrich, Cat. No. S5512) and developed by chemolumi-
nescence (Supersignal West Femto Luminol, Thermo
Scientific, Cat. No. 1856189). The level of fucosylation
of Hp alpha was obtained by densitometric analysis
(GS-800 Calibrated Densitometer, Bio-Rad) using the
Quantity One software for PC (Bio-Rad).
Detection of fucosylated Hp alpha in ovarian carcinoma
tissues by confocal microscopy
Paraffin-fixed biopsies from four ovarian cancer patients
and one sample of cancer-free ovarian tissue removed from
a patient diagnosed with endometriosis were assessed
using a standard histo-immunofluorescence method.
Fucosylated-Hp was detected by co-localization of Hp
with a primary anti-haptoglobin antibody as describedabove, and a secondary TRITC-conjugated antibody (goat
anti-mouse IgG-TRITC conjugated, Sigma Aldrich, Cat. No.
A16077). Fucosylation levels were detected with biotinylated
AAL and visualized with Streptavidin-FITC (Life Technolo-
gies, Cat. No. 43–4311). Cell nuclei were stained with 4′, 6-
diamidino-2-phenylindole dihydrochloride (DAPI) (Sigma
Chemical Co., St. Louis, MO, USA). Tissue sections incu-
bated with secondary reagents (antibody or streptavidin
alone) served as negative controls. Fluorescent images
(10X: tile scan of 5 x 5, 40X, and 63X) were obtained
using a Confocal Carl Zeiss LMS 700 microscope that
operates with up to four stable, solid-state lasers and
wavelengths of 405 to 639 nm. Images were analyzed
with the Zen 2011 ‘blue edition’ software. Fluorochromes
used were DAPI (4′, 6-diamidino-2-phenylindole dihy-
drochloride) with excitation and emission wavelengths of
350 and 470 nm, respectively; Fluorescein isothiocyanate
(FITC), with excitation and emission wavelengths of 490
and 525 nm, respectively; and Tetramethyl Rhodamine
Isothiocyanate (TRITC) with excitation and emission
wavelengths of 557 and 576 nm, respectively.
Statistical analyses
Statistical analyses were performed using STATA v. 12.0
for Windows 2010. A scatter plot graphic was used to
show the relationship between two groups of data: the
number of detected proteins by 2D electrophoresis of
each sample, versus the clinical stage of each patient. The
frequency of different genotypes of alpha isoforms of Hp
was determined by producing a histogram of frequencies
among the tested population. To determine the relation
between fucosylation and clinical stage, a Spearman’s rank
correlation coefficient was obtained and results were con-
sidered significant with a p ≤ 0.05. Finally, a stacked histo-
gram plot was created to visualize the distribution of the
fucosylation level of Hp alpha with respect to the clinical
stage of the illness.
Results
After reviewing clinical records of 50 patients, we were
able to guarantee the presence of the 5 histologies of the
epithelial ovarian cancer, with a higher incidence of the
papillary serous type which corresponds with data re-
ported worldwide (www.ovariancancer.org/); all the pa-
tients with ovarian carcinoma selected for this study
produced ascitic fluid. The average age was 52 years,
10 years less than that reported by the American Cancer
Society (www.cancer.org/). Table 1 shows the family his-
tory data associated with ovarian, breast and colorectal
cancer.
Analysis of differential expression of proteins in body
fluids such as ascitic fluid allows the detection of proteins
involved in different processes, such as proliferation and
metastasis. In this study, we show the proteomic analysis
Table 1 Clinical data of ovarian carcinoma patients
Characteristics Percentage (n)
Histopathologic types
Papillary serous 74 (37)
Mucinous 12 (6)
Endometrioid 6 (3)
Clear cells 4 (2)
Poorly differentiated 4 (2)








Family history of cancer
YES 26 (13)
NO 74 (37)
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Figure 1 shows the protein profile used as a reference
pattern after the elimination of abundant proteins. This
elimination process allowed the visualization of more
than 250 spots that were resolved for each 2D gel of
the 50 samples analyzed.
A zone showing a differential protein expression pat-
tern (Figure 1, black square) was selected, where it was
possible to distinguish several spots in every sample. In-
side this square as many as nine spots, with highly dis-
tinctive expression patterns were detected. To compare
samples, Melanie 7.0 software (http://world-2dpage.
expasy.org/melanie/) was used, which is a platform that
allows the qualitative and quantitative evaluation ofFigure 1 Detection and selection of a differential expression profile z
ascitic fluid sample with more than 250 proteins resolved, after elimination
showing nine protein spots, present in 100% of samples, was selected (blac
and a closer view of the resolution of the corresponding spots (a-g).protein profiles from bidimensional electrophoresis gels
(Additional file 1: Figure S1A). To perform large-scale
comparative studies, the software eliminates varia-
tions between experiments and detects differential
expression profiles. These differential expression pro-
files were validated using densitometric analysis of the
selected area, where notable variations in at least seven of
the nine spots were observed; whereas the last two spots
showed a similar behavior (Additional file 1: Figure S1B).
The profile of proteins achieved under these conditions
was reproducible among samples, and the identification of
the nine spots was achieved by Mass Spectrometry
(MALDI-TOF). Results indicated that seven spots corre-
sponded to Hp alpha 1 isoforms (a-g) and the remaining
two spots (h and i) corresponded to isoforms of Trans-
thyretin (Table 2).
We then proceeded to detect protein expression
changes among clinical samples. A comparative analysis
of the nine spots previously selected, in 20 representative
samples of the 50 analyzed is shown (Figure 2A). Results
of this analysis showed that Transthyretin isoforms
retained a constant expression and concentration pattern
in all the analyzed samples. In comparison, Hp alpha
showed differential expression patterns and different con-
centration levels. The molecular weight of the isoforms
was of 28 kDa (isoforms a-d) and of 18 kDa (isoforms e-g)
(Figure 2A). Human Hp is formed by a tetramer with two
subunits, described as α2β2. There are three genotypes of
Hp alpha subunit: Hp 1–1, Hp 1–2 and Hp 2–2, which
differ in their structure and size. During the ascitic fluid
analyses, two genotypes of the alpha subunit were found,
one of the seven spots (b spot) was identified as an alpha
2 isoform, and the six remaining spots corresponded toone. Silver staining pattern of a representative 15% SDS-PAGE of an
of abundant proteins; an area with a differential expression profile
k square); schematic representation of the differential expression area







Mr pI Mr pI
1 Haptoglobin isoform 1 preproprotein [Homo sapiens] gi|4826762 45861 6.13 28.9 6.4 86 0.0012
2 hp2-alpha [Homo sapiens] gi|296653 42126 6.25 28.9 6.2 111 9.5e-05
3 Haptoglobin isoform 1 preproprotein [Homo sapiens] gi|4826762 45861 6.13 28.9 6.6 87 0.00097
4 Haptoglobin isoform 1 preproprotein [Homo sapiens] gi|4826762 45861 6.13 28.2 5.9 63 0.011
5 Haptoglobin isoform 1 preproprotein [Homo sapiens] gi|4826762 45861 6.13 18.9 5.9 58 0.029
6 Haptoglobin isoform 1 preproprotein [Homo sapiens] gi|4826762 45861 6.13 18.1 6.2 75 0.017
7 Haptoglobin isoform 1 preproprotein [Homo sapiens] gi|4826762 45861 6.13 18.2 5.5 59 0.028
8 Transthyretin [Homo sapiens] gi|48145933 15991 5.52 20.2 6.1 94 0.0002
9 Transthyretin [Homo sapiens] gi|48145933 15991 5.52 20.2 5.9 115 1.6e-06
Garibay-Cerdenares et al. Journal of Ovarian Research 2014, 7:27 Page 5 of 12
http://www.ovarianresearch.com/content/7/1/27the alpha 1 isoform. With the data obtained by mass spec-
trometry, we analyzed the presence of Hp alpha genotypes
in the ascitic fluids of the patients. The results show that
in the Mexican population analyzed in this study, the most
prevalent genotype was Hp alpha 1–2 (70%), and the less
frequent was the Hp alpha 1–1 genotype (30%). The Hp
alpha 2–2 genotype was absent (Figure 2B). The genetic
variation of the alpha 1–2 Hp isoform has been associated
with the prevalence and clinical evolution of many inflam-
matory diseases [11].Figure 2 Phenotypes and genotypes of haptoglobin alpha isoforms in
from 20 different and independent samples, representative of the total 50 sam
were processed for 2D after HAS/IgG depletion. B). Hp alpha genotypes (1–1,
C). Graph showing the number of protein spots detected by 2D in the selecteTo establish a probable association between the number
of Hp alpha isoforms and the clinical stage of the patients’
illness, a scatter plot graphic was produced. Results sug-
gest that clinical stage IV samples (44% of total samples),
correlate with a higher number of spots of this protein; of
these, 81.8% had from 7 to 9 spots, whereas only 73% of
clinical stage IIIC samples (52% of total samples) had from
7 to 9 spots (Figure 2C).
Several studies have identified Hp, particularly the gly-
cosylated forms produced by fucosylation, whose levelsMexican patients. A). Selected area of the protein profiles obtained
ples collected for this study. Protein samples (50 μg) from ascitic fluids
1–2, 2–2) present in all 50 samples were determined and counted.
d area for each of the 50 patients according to their clinical stage.
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tients [23-25]. To see whether Hp alpha isoforms,
present in ascitic fluids, were fucosylated, specific-ligand
binding assays using biotinylated Aleuria aurantia lectin
(AAL) were performed. The presence of total Hp was
monitored by the western blot method using a commer-
cial anti-Hp monoclonal antibody. Figure 3A shows the
profiles of HpT (beta and two alpha isoforms) in ascitic
fluids from 40 patients. This analysis included an ascitic
fluid sample not related to cancer (NR), as well as a
commercial Hp standard (ST). It is noteworthy that a
differential degree of fucosylation (HpF) is appreciated in
the alpha chain of Hp, shown in the bottom panels of
both filters, which highlights in some samples, the pres-
ence of two fucosylated alpha chains (18 and 28 kDa).
The absence of fucosylation of the Hp standard (purified
from healthy human sera), and that from a non-cancer re-
lated sample from a hepatic cirrhosis case, suggest that this
post-translational modification is only present in Hp from
ascitic fluid samples derived from ovarian cancer patients.
The differential level of Hp fucosylation was analyzed
in a scatter plot graphic using densitometry and clinical
staging. The results show a trend of higher fucosylation
of Hp alpha in stage IV cases (Figure 3B).
Fucosylation levels determined by densitometric analysis
were classified as high, medium, or low. It was then pos-
sible to establish the relationship between the levels of fuco-
sylation with respect to the clinical stage of the patients
analyzed. Results show that in samples from patients atFigure 3 Fucosylation profile of haptoglobin. A). Haptoglobin standard
fluid samples from ovarian cancer patients were analyzed for fucosylation o
abundant proteins were processed through a 12.5% SDS-PAGE and transfe
(1:1000), specific for fucose residues; variable levels of fucosylation were de
Streptavidin (1:2000) (lower left panel) or with Horseradish Peroxidase-conju
same samples were incubated with an anti-Hp antibody that recognizes th
antibody conjugated with Horseradish Peroxidase (1:1000) (upper right pan
panel). B). Graph showing densitometric values of samples’ fucosylation in
related sample. C). Fucosylation levels (low, medium or high) of samples, astage IV (68.4%), 53.8% were highly fucosylated. In com-
parison, samples from patients at stage IIIC (31.6%) showed
a more heterogeneous pattern of fucosylation, where from
these, 25% had low fucosylation levels, 33.3% had medium
level and 41.7% showed high levels of fucosylation
(Figure 3C). To analyze the statistical significance of the dif-
ferences in fucosylation of the Hp alpha isoform and its
possible correlation with the clinical stage of each patient, a
Spearman correlation between these criteria was produced.
A directly proportional relationship, statistically significant,
was found between fucosylation levels and advanced clin-
ical stage of the patients (rs = 0.6664, p ≤ 0.05). This estab-
lished that the clinical stage IV is associated with a higher
level of fucosylation of Hp alpha.
The presence of fucosylated Hp alpha in cancer tissues
has been described previously [26]. However, there are still
two unanswered questions regarding the fucosylation of
Hp: one is whether cancer cells themselves produce fucosy-
lated Hp; the other one is whether cell transformation pro-
duces a factor which induces the production of fucosylated
Hp in the liver [27]. To answer the first question, western
blotting assays and specific ligand binding assays with AAL
were carried out to establish if fucosylated Hp is produced
in situ in cancer tissues. The presence of fucosylated Hp
was detected in tumors developed in immunodeficient
mice, using the ovarian cancer cell line SKOV-3 (Figure 4A).
To corroborate the presence of fucosylated Hp in human
ovarian cancer tissues, immunohistological assays were per-
formed by confocal microscopy, where a tile scan analysis(ST), an ascitic fluid sample non-related with cancer (NR), and 40 ascitic
f haptoglobin alpha. Protein samples (50 μg) from ascitic fluid free of
rred to a NCP to incubate with biotinylated-Aleuria aurantia lectin
tected by a colorimetric system using Alkaline Phosphatase-conjugated
gated Streptavidin (1:1000) (lower right panel). As loading control, the
e β, α1 and α2 isoforms of Hp to detect total Hp, and a secondary
el) or Alkaline Phosphatase-conjugated antibody (1:1000) (upper left
arbitrary units, comparing clinical stages IIIC and IV vs. a non-cancer
ccording to clinical stages.
Figure 4 (See legend on next page.)
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Figure 4 Immunolocalization of haptoglobin and its fucosylation state in ovarian carcinoma. A). Detection of total (HpT) and fucosylated
Hp (HpF) in a Hp commercial standard (ST) and a tissue extract from an ovarian tumor developed in Nu/Nu mice (T) by Western blot and lectin
binding assays (as described in figure 3). B, C, E). Immunolocalization of Hp, fucosylated Hp and fucosylation. Tissue nuclei were stained with
DAPI (blue) to help define the tissues’ structures; Hp was stained with a primary anti-Hp antibody and was developed with a secondary TRITC
coupled antibody (red); fucosylation was detected by biotinylated-Aleuria aurantia lectin followed by FITC coupled streptavidin (green). All
reagents were used at a 1:100 dilution and the scale bar = 100 μm. B).Histo-immunofluorescence of stromal and epithelial (a) and germinal (b)
areas of cancer-free ovarian tissue slices. The analysis of tile scan shows a tridimensional image generated by 25 fields’ caption (left panels); from
the tile scan, an area was selected (yellow square) and optical zooms were done twice (10X and 40X). Epithelium (E), stroma (S), and follicles (F).
C). Tumor tissue sections from four different patients. Fucosylation of Hp was analyzed in broad zones (5x5) of tissues as a tile-scan analysis. A
representative region (yellow box) of each tissue was selected to detect fucosylated Hp in optical zooms. D). Graph showing a semi-quantitative
analysis of nuclei, Hp and fucosylation content, considering an average area. This analysis was performed with the Software Zen 2011 (blue
edition, Carl Zeiss) determining the mean fluorescence intensity for each molecule of interest given in arbitrary units. E). Immunolocalization of
fucosylated Hp in individual cells in an optical zoom from a selected region of a tumor tissue section; the crop section analyzed (yellow box)
clearly shows the cytoplasmic distribution of fucosylated Hp with approximately 80% of co-localization found in each selected cell.
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of the tissues. The distribution patterns of Hp (red), fucosy-
lation (green) and fucosylated Hp (yellow) were observed.
Results in Figure 4B show the presence of fucosylated Hp
in cancer-free ovarian tissue; this glycoprotein was located
mainly inside clearly-defined follicles at any developmental
stage (F), but not in superficial epithelium (E) or cortical
stroma (S). Basal fucosylation (green) levels were found in
stroma, but none in the epithelium. Figure 4C shows the
results obtained with three different histotypes of ovarian
cancer (papillary serous, endometrioid and clear cell). An
over-expression of fucosylation, most probably of a wide
variety of proteins broadly distributed in all tissues in
comparison with cancer- free tissues, not only in sur-
face epithelium but also in the stroma, was observed. A
wide distribution of patch-like patterns in internal and
cortical stroma; and a clearly delimited pattern present
in membranes of the surface epithelium were found. In
areas of highly differentiated tissue, the level and distri-
bution of fucosylated Hp alpha was limited, with a co-
localization ratio not higher than 20%. However, in
undifferentiated zones of the tissues where certain dis-
aggregated cells can be found, the presence of fucosy-
lated Hp was higher with a colocalization ratio of 60%.
Non-fucosylated Hp was clearly seen in all cancer tis-
sues; however, its presence was minimal in comparison
with fucosylation levels. Figure 4D shows histograms of
fluorescence intensity. These results show that three differ-
ent processes are occurring in ovarian cancer in compari-
son to cancer-free tissues: higher levels of fucosylation,
non-fucosylated and fucosylated Hp (Figure 4D). Optical
zoom images carried out with two of the biopsies allowed
us to define more precisely the subcellular localization
of fucosylated Hp in tumor cells (Figure 4E). The left
panels show the presence of cells which are part of the
tumor tissue, expressing intracytoplasmic fucosylated
Hp. It can also be appreciated that there is expression of
another kind, yet to be identified, of highly fucosylated
proteins in cell membranes.Discussion
Over more than three decades of clinical use, CA-125
has proven to be one of the most useful tumor markers
in cancer medicine; the major clinical utility of this
serum marker is in following the clinical course and the
evaluation of the effectiveness of new antineoplastic
agents against ovarian cancer [28]. However, it is associ-
ated with a high false-positive rate among women with
benign gynaecological conditions such as endometriosis
[15]. Furthermore, CA125 has very low sensitivity in
identifying patients with early-stage ovarian cancer [29].
HE4 (human epididymal secretory protein E4; WAP
four-disulphide core domain protein 2) alone or in combin-
ation with CA125 [30,31], are the only two biomarkers US
FDA approved for monitoring of disease recurrence or pro-
gression, but not for screening. Recently, there has been a
resurgence of efforts to identify ovarian cancer biomarkers.
Broadly studied are mesothelin [14]; transthyretin [32];
ApoA1 [33]; IL-6 and IL-8 [34] and serum amyloid A [35]
for using in initial detection, staging, disease prognosis, or
VEGF studied as a possible molecular therapeutic target.
BRCA1 and BRCA2 have been used, alone or in combin-
ation, for an individualized clinical management of patients
[36,37], to establish the sensitivity or resistance to chemo-
therapy. Therefore, the search for new biomarkers useful in
the early diagnosis of ovarian cancer continues.
Acute-phase proteins are synthesized by the liver as a
nonspecific response to inflammation, with the primary
function of modulating the inflammatory response to
avoid tissue damage or infection [38]. Haptoglobin, an
acute-phase glycoprotein, is produced mainly in the liver
where it is released into the blood circulation. This pro-
tein also participates in the formation of new blood ves-
sels and vascular remodeling [26,39-42].
The presence of Hp in patients’ sera with ovarian can-
cer and its possible use as a biomarker for the diagnosis
of this disease has been suggested previously [43]. More-
over, using ascitic fluid from ovarian cancer patients and
mass spectrometry, Faça et al., [44] suggested that the
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date. Although the correlation between Hp expression
and ovarian carcinoma has been widely reported [45,46],
this is the first study in which it is possible to distinguish
differential alpha subunit expression together with differ-
ential levels of fucosylation. Our results suggest that the
differential expression pattern of isoforms of Hp alpha
and the conserved expression profile of Transthyretin
might correspond to a signature for each patient, and
whose pattern could be representative of the ovarian can-
cer ascitic fluid stage. Moreover, the genetic prevalence of
Hp 1–2, which has been associated with other pathologies
of clinical importance, allowed us to establish a significant
relationship between the patient Hp alpha pattern and the
clinical progress of the disease [11].
Post-traductional modifications of proteins may play im-
portant roles in many types of cancer [47]. Increased levels
of fucosylation have been reported in a number of patho-
logical conditions, including several cancer types (cervical,
gastrointestinal, pancreatic, and breast and ovarian cancer)
[26,48-53]. The fucosylation profiles from the alpha sub-
unit of Hp showed that those patients with most advanced
stages of cancer expressed the highest levels of fucosyla-
tion, suggesting a possible role for fucosylated Hp during
the progress of ovarian carcinoma. Our results are in
agreement with those described previously, which corre-
lated fucosylation levels of Hp with disease progression in
breast cancer [51], gastrointestinal cancer [49], and in
adenocarcinoma of the uterus [54]. However, the examin-
ation of a greater number of clinical cases is required to
confirm this hypothesis.
Since ascites occurs in patients only at advanced stages
of the disease, it is important to assess the expression
profile of fucosylated Hp in tumor tissues. Differences in
the expression of Hp and fucosylated Hp in those tissues
in comparison with cancer-free samples were evident.
On the one hand, we show for the first time the presence
of fucosylated Hp within cancer-free human ovarian folli-
cles. The localization of Hp in healthy ovaries and the pos-
sibility that it may play a role in human reproduction has
been analyzed; clinical findings depicted the Hp expression
pattern in various organs of the reproductive system: the
rat ovary [55], the mouse uterus and ovary [56] and the
rabbit uterus [57]. The presence of Hp has been reported
in human reproductive tissues, as uterus [58] and follicular
fluid [59], as a measure of ovary quality.
The differential distribution of fucosylation in tissues
of at least three of the five histological types analyzed,
in comparison with basal fucosylation observed in
cancer-free tissue, suggest two possible directions for
further investigation: the involvement of fucosyltrans-
ferases overexpression in the process of fucosylation
and the identification of highly fucosylated proteins in
the initial stages of ovarian cancer.Even though the liver is considered as the major site for
Hp expression, the stimulation with bacterial lipopolysac-
charide (LPS) has demonstrated that Hp synthesis can be
induced not only in the liver but also in other tissues, in-
cluding lung, skin, spleen, and kidney [60]. Elevation of this
peptide has been observed in infections, inflammations,
and various malignant diseases, including lung and bladder
cancers [61], leukemia [62], breast cancer [63], malignant
lymphoma [64,65], urogenital tumors [66], esophageal
squamous cell carcinoma [67] and serum and ascitic fluid
of patients with ovarian cancer [68] in comparison to
healthy tissue. In this work we provide evidence to sup-
port that in addition to the liver as a source of Hp, there is
an important participation of tumoral cells in fucosylated
Hp production, mainly in tumor zones with higher disin-
tegration and cellular de-differentiation, suggesting a pos-
sible role for Hp in the migration of cancer cells.
Moreover, the potential of this work lies in the fact that
we are proposing not just haptoglobin as biomarker, but
to consider also the number of differential isoforms of
alpha haptoglobin and their level of fucosylation present
in the tumor tissue. This opens the possibility to deter-
mine if these isoforms, glycated or not, could be detected
in serum, and if the fucosylation of tissular haptoglobin
could help to distinguish between a healthy and a malig-
nant tissue through the analysis of biopsies newly obtained
from patients in hope of some diagnosis, whether it be in
ovarian cancer or another. Still, there are some limitations
within the study, mainly because the number of analyzed
samples does not allow setting haptoglobin, in a definitive
way, as a specific biomarker for ovarian cancer or its early
detection, because it would be necessary to analyze sam-
ples from stages I and II. Based on the results obtained, at
this moment it is difficult to assign clinical implications
for haptoglobin detection; however the difference in the
levels of fucosylation between healthy and malignant tis-
sues was very clear, which means that there must be many
other fucosylated proteins in malignant tissues.
The use of a glycomic approach, has allowed the iden-
tification of a number of tumor marker candidates, find-
ing that fucosylated haptoglobin in sera could be a
possible tumor marker for several kinds of cancer types.
A detection kit for pancreatic cancer via a sandwich
enzyme-linked immune sorbent assay using Aleuria aur-
antia lectin and the Fab portion of anti-haptoglobin
antibody has been reported [69]. Positive rates of fucosy-
lated haptoglobin with this method were significantly
higher in patients of stage IV pancreatic cancer, com-
pared with other clinical stages.
At this moment, we would not dare to recommend pa-
tients to undergo tests to determine if there is fucoys-
lated Haptoglobin alpha isoforms in ascitic fluids, but
indeed, this is a very good perspective for this work, i.e.,
to establish a simple, low-cost laboratory test, while
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required to convert to fucosylated haptoglobin in a reli-
able biomarker together with CA125 or computerized
axial tomography to evaluate the ability of complete re-
section, or to follow if there is response to drug therapy.
Without leaving aside that the process of fucosylation
could also become a very important early marker of cel-
lular transformation.
Conclusion
Based on the above results, we propose that increased
numbers of highly fucosylated Hp alpha isoforms in ascitic
fluids as well as the presence of fucosylated Hp in tumor
tissues of Mexican ovarian cancer patients are associated
with advanced stages of the disease; and reinforce the po-
tential of fucosylated Hp alpha isoforms to be used as bio-
markers for disease progression.
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